Search

Your search keyword '"Di Marco, Vito"' showing total 728 results

Search Constraints

Start Over You searched for: Author "Di Marco, Vito" Remove constraint Author: "Di Marco, Vito"
728 results on '"Di Marco, Vito"'

Search Results

1. A holistic evaluation of patients with chronic Hepatitis D virus (HDV) infection enrolled in the Italian PITER-B and delta cohort

2. Real-world experience with long-term albumin in patients with cirrhosis and ascites☆

3. Oesophageal varices predict complications in compensated advanced non-alcoholic fatty liver disease

5. Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination

6. Development of a Thalassemia International Prognostic Scoring System (TIPSS)

7. SAT-113 Long-term therapy with intravenous human albumin increase survival in patients with decompensated cirrhosis and refractory ascites

8. FRI-078-YI Long-term albumin administration in outpatients with decompensated cirrhosis and diabetes mellitus: post-hoc analysis of the ANSWER trial database

9. FRI-047-YI Predictors of ascites resolution in patients with cirrhosis receiving long-term albumin treatment. Results from a real-world study in Italy (Real-ANSWER)

10. SAT-209-YI A Markov model unveiling the impact of Resmetirom on the natural history of MASLD patients with baseline significant or severe liver fibrosis

11. Factors Associated with Primary Liver Cancer Survival in a Southern Italian Setting in a Changing Epidemiological Scenario

12. Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies

14. Metabolic comorbidities and male sex influence steatosis in chronic hepatitis C after viral eradication by direct-acting antiviral therapy (DAAs): Evaluation by the controlled attenuation parameter (CAP)

16. Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease

20. Update of the statements on biology and clinical impact of occult hepatitis B virus infection

21. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients

23. Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals

24. AISF position paper on HCV in immunocompromised patients

25. Risk of liver-related events in metabolic dysfunction–associated steatohepatitis (MASH) patients with fibrosis: A comparative analysis of various risk stratification criteria.

26. Risk of liver-related events in metabolic dysfunction–associated steatohepatitis (MASH) patients with fibrosis: A comparative analysis of various risk stratification criteria

28. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents

29. Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis

31. Epidemiological and clinical profile of HDV infected people in care in Italy: interim analysis from the ongoing PITER cohort

32. Programmed cell death 1 genetic variant and liver damage in non-alcoholic fatty liver disease

33. Real-word experience of long-term albumin treatment in a large cohort of patients with cirrhosis and ascites (Real-Answer study)

34. Presence and severity of esophageal varices drives portal hypertension-related complications in compensated advanced non-alcoholic fatty liver disease

36. RESIST criteria accurately rule-out high-risk esophageal varices in patients with primary biliary cholangitis and compensated advanced chronic liver disease

37. Risk factors for viral reactivation in patients with overt or occult HepatitisB Virus infection receiving immunosuppressive treatments: a systematic review and meta-analysis

39. Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel

42. Glecaprevir/Pibrentasvir is safe and effective in Italian patients with chronic hepatitis C aged 75 years or older: A multicentre study

43. Programmed cell death 1 genetic variant and liver damage in nonalcoholic fatty liver disease

44. Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination

46. Oesophageal varices predict complications in compensated advanced non-alcoholic fatty liver disease

47. Dual therapy with peg-interferon and ribavirin in thalassemia major patients with chronic HCV infection: Is there still an indication?

48. MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease

49. Changing HCV patient profiles: insights from a large multinational real-world sofosbuvir/velpatasvir (SOF/VEL) dataset

50. Global Real-World Evidence of Sofosbuvir/Velpatasvir as a Highly Effective Treatment and Elimination Tool in People with Hepatitis C Infection Experiencing Mental Health Disorders

Catalog

Books, media, physical & digital resources